Abstract 1951P
Background
Angiosarcoma is a rare and aggressive cancer of the endothelial cells. It has been shown that β-adrenergic signaling through the β-adrenoceptors (ADRB) 1 and 2, that are overexpressed in angiosarcoma, promotes tumor growth. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been demonstrated in several case reports. The aim of this window-of opportunity trial was to prospectively evaluate the anti-tumor activity of propranolol in patients with angiosarcoma.
Methods
Patients with angiosarcoma with a waiting time of 3 to 6 weeks until start of standard treatment were eligible. Propranolol was dosed 80 mg to 240 mg/day according to a dose titration schedule. The primary endpoint was clinical response rate. Clinical response was defined as either complete response (CR), partial response (PR) (according to RECIST 1.1) or stable disease (SD) with improvement of erythema, edema and thickness. Exploratory objectives included histologic response, PET response and assessment of potential biomarkers for response in tumor tissue by IHC (e.g., ADBR 1/2, PD-L1).
Results
To date, 13 patients with a median age of 67 years (range 52-86) are enrolled and have initiated treatment. The median duration of treatment was 28 days (range 21-42 days). The median dose was 160 mg/day. Three patients showed exceptional good tolerance (blood pressure/heart rate) and could be escalated to the highest dose (240 mg/day). Two patients showed clinical response. The most common adverse event was grade 1/2 bradycardia (85%). There were no grade ≥3 adverse events. Preliminary IHC results showed ADBR2 overexpression in the majority of the tumors (12 out of 17 tumor samples, both in responders and non-responders). None of the tumors showed ADBR1 overexpression.
Conclusions
This window-of-opportunity trial did not demonstrate clinical efficacy of propranolol monotherapy in patients with angiosarcoma. Two out of 13 patients did however show clinical benefit. ADBR1 or 2 expression did not correlate with response. Translational research to better comprehend the anti-tumor activity of propranolol for adequate selection of patients in future studies is ongoing (e.g., immune system-based biomarkers).
Clinical trial identification
NCT04518124.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Anticancer Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15